¼¼»ó¿¡¼­ °¡Àå°­·ÂÇÑ À¥»çÀÌÆ®

ºñÁî´Ï½º Áö¿ø

ÀÎÇã°¡ °¡À̵å¶óÀÎ ÀÚ·á½Ç

ÀÎÇã°¡ °¡À̵å¶óÀÎ ÀÚ·á½Ç

Ä«Å×°í¸® ÀǾàǰ
Á¦¸ñ [½ÄǰÀǾàǰ¾ÈÀüó] °³ÀÎ ¸ÂÃãÇü ½Å»ýÇ׿ø Ä¡·áÁ¦ °³¹ß½Ã °í·Á»çÇ× °¡À̵å¶óÀÎ(¹Î¿øÀξȳ»¼­)(¿µ¹®º»)
ÀÛ¼ºÀÚ kbihealth
µî·ÏÀÏ 2024-10-04
Á¶È¸¼ö 227
½ÄǰÀǾàǰ¾ÈÀüÆò°¡¿ø¿¡¼­´Â °³ÀÎ ¸ÂÃãÇü ½Å»ýÇ׿ø Ä¡·áÁ¦ °³¹ß½Ã °í·Á»çÇ× °¡À̵å¶óÀÎ(¹Î¿øÀξȳ»¼­)(¿µ¹®º»)À» °³Á¤/¹ß°£ÇÏ¿´À¸´Ï °ü·Ã ¾÷¹«¿¡ Âü°íÇϽñ⠹ٶø´Ï´Ù. (Considerations on the Development of Personalized Neoantigen-Targeted Therapy Products)


°¨»çÇÕ´Ï´Ù.
÷ºÎÆÄÀÏ
°³ÀÎ ¸ÂÃãÇü ½Å»ýÇ׿ø Ä¡·áÁ¦ °³¹ß½Ã °í·Á»çÇ× °¡À̵å¶óÀÎ(¹Î¿øÀξȳ»¼­)(¿µ¹®º»).pdf ´Ù¿î·Îµå : 143